Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
George Vasquez-Rios & Girish N Nadkarni. (2020) SGLT2 Inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients. International Journal of Nephrology and Renovascular Disease 13, pages 281-296.
Read now
Read now
Marc S Rendell. (2019) The journey from gene knockout to clinical medicine: telotristat and sotagliflozin. Drug Design, Development and Therapy 13, pages 817-824.
Read now
Read now
Marc S. Rendell. (2018) Efficacy and safety of sotagliflozin in treating diabetes type 1. Expert Opinion on Pharmacotherapy 19:3, pages 307-315.
Read now
Read now
Bertrand Cariou & Bernard Charbonnel. (2015) Sotagliflozin as a potential treatment for type 2 diabetes mellitus. Expert Opinion on Investigational Drugs 24:12, pages 1647-1656.
Read now
Read now
Articles from other publishers (10)
Al-Anood Al-Shamasi, Rozina Elkaffash, Meram Mohamed, Menatallah Rayan, Dhabya Al-Khater, Alain-Pierre Gadeau, Rashid Ahmed, Anwarul Hasan, Hussein Eldassouki, Huseyin Cagatay Yalcin, Muhammad Abdul-Ghani & Fatima Mraiche. (2021) Crosstalk between Sodium–Glucose Cotransporter Inhibitors and Sodium–Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases. International Journal of Molecular Sciences 22:23, pages 12677.
Crossref
Crossref
Jaspreet Kalra, Suresh Babu Mangali, Deepika Dasari, Audesh Bhat, Srashti Goyal, Indu Dhar, Dharamrajan Sriram & Arti Dhar. (2019) SGLT1 inhibition boon or bane for diabetes‐associated cardiomyopathy. Fundamental & Clinical Pharmacology 34:2, pages 173-188.
Crossref
Crossref
Lin-jie Zhu, Lin Chen, Chong-fei Bai, An-guo Wu, Si-cheng Liang, Fei-hong Huang, Shou-song Cao, Le Yang, Wen-jun Zou & Jian-ming Wu. (2020) A rapid and sensitive UHPLC-MS/MS method for the determination of ziyuglycoside I and its application in a preliminary pharmacokinetic study in healthy and leukopenic rats. Biomedicine & Pharmacotherapy 123, pages 109756.
Crossref
Crossref
Chiara Maria Assunta Cefalo, Francesca Cinti, Simona Moffa, Flavia Impronta, Gian Pio Sorice, Teresa Mezza, Alfredo Pontecorvi & Andrea Giaccari. (2019) Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Cardiovascular Diabetology 18:1.
Crossref
Crossref
Kajal Patel & Antonia Carbone. (2019) Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial Data. Annals of Pharmacotherapy 53:12, pages 1227-1237.
Crossref
Crossref
Reyhaneh Moradi‐Marjaneh, Maryam Paseban & Amirhossein Sahebkar. (2019) Natural products with SGLT2 inhibitory activity: Possibilities of application for the treatment of diabetes. Phytotherapy Research 33:10, pages 2518-2530.
Crossref
Crossref
Lea El Hage, Sangeeta R Kashyap & Pratibha Rao. (2020) Use of SGLT-2 Inhibitors in Patients With Type 1 Diabetes Mellitus. Journal of Primary Care & Community Health 10, pages 215013271989518.
Crossref
Crossref
Rory J. McCrimmon & Robert R. Henry. (2018) SGLT inhibitor adjunct therapy in type 1 diabetes. Diabetologia 61:10, pages 2126-2133.
Crossref
Crossref
Thomas DanneTorben BiesterOlga Kordonouri. (2018) Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care. Diabetes Technology & Therapeutics 20:S2, pages S2-69-S2-77.
Crossref
Crossref
David R. Powell, Melinda G. Smith, Deon D. Doree, Angela L. Harris, Jennifer Greer, Christopher M. DaCosta, Andrea Thompson, Sabrina Jeter-Jones, Wendy Xiong, Kenneth G. Carson, Nicole C. Goodwin, Bryce A. Harrison, David B. Rawlins, Eric D. Strobel, Suma Gopinathan, Alan Wilson, Faika Mseeh, Brian Zambrowicz & Zhi-Ming Ding. (2017) LX2761, a Sodium/Glucose Cotransporter 1 Inhibitor Restricted to the Intestine, Improves Glycemic Control in Mice. Journal of Pharmacology and Experimental Therapeutics 362:1, pages 85-97.
Crossref
Crossref